Cargando…
Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
Antibody drug conjugates (ADCs), consisting of a cancer-specific antibody and cytotoxic payload, are shown to be a potent class of anticancer therapeutics, with enhanced therapeutic efficacy and reduced “off-target” side effects. However, the therapeutic window of ADCs is narrowed by problems such a...
Autores principales: | Kim, Hyun Jung, Sung, Ho Jin, Lee, Yul Min, Choi, Sun Il, Kim, Yun-Hee, Heo, Kyun, Kim, In-Hoo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7246698/ https://www.ncbi.nlm.nih.gov/pubmed/32384770 http://dx.doi.org/10.3390/ijms21093286 |
Ejemplares similares
-
Breast cancer stem cells in HER2-negative breast cancer cells contribute to HER2-mediated radioresistance and molecular subtype conversion: clinical implications for serum HER2 in recurrent HER2-negative breast cancer
por: Kim, Yun Gyoung, et al.
Publicado: (2017) -
HER2 signaling regulates HER2 localization and membrane retention
por: Jeong, Jaekwang, et al.
Publicado: (2017) -
An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers
por: Shin, Seol Hwa, et al.
Publicado: (2021) -
Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy
por: Jeong, Hwa Yeon, et al.
Publicado: (2020) -
HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates
por: Ocaña, Alberto, et al.
Publicado: (2020)